DE10346487A1 - Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels - Google Patents

Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels Download PDF

Info

Publication number
DE10346487A1
DE10346487A1 DE10346487A DE10346487A DE10346487A1 DE 10346487 A1 DE10346487 A1 DE 10346487A1 DE 10346487 A DE10346487 A DE 10346487A DE 10346487 A DE10346487 A DE 10346487A DE 10346487 A1 DE10346487 A1 DE 10346487A1
Authority
DE
Germany
Prior art keywords
cell
tissue
rna
dnazyme
target cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10346487A
Other languages
English (en)
Inventor
Serdar Sel
Harald Renz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philipps-Universitaet Marburg 35037 Marburg De
Original Assignee
Transmit Gesellschaft fuer Technologietransfer mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmit Gesellschaft fuer Technologietransfer mbH filed Critical Transmit Gesellschaft fuer Technologietransfer mbH
Priority to DE10346487A priority Critical patent/DE10346487A1/de
Priority to ES04802618T priority patent/ES2304633T3/es
Priority to SI200430734T priority patent/SI1670919T1/sl
Priority to DK07013576T priority patent/DK1857555T3/da
Priority to PT04802618T priority patent/PT1670919E/pt
Priority to KR1020067008072A priority patent/KR101121818B1/ko
Priority to EP04802618A priority patent/EP1670919B1/de
Priority to DE502004008802T priority patent/DE502004008802D1/de
Priority to US10/574,560 priority patent/US8119789B2/en
Priority to PL04802618T priority patent/PL1670919T3/pl
Priority to ES07013576T priority patent/ES2320706T3/es
Priority to PL07013576T priority patent/PL1857555T3/pl
Priority to EP07013576A priority patent/EP1857555B1/de
Priority to DE502004006791T priority patent/DE502004006791D1/de
Priority to JP2006529624A priority patent/JP5013870B2/ja
Priority to PCT/DE2004/002197 priority patent/WO2005033314A2/de
Priority to AT04802618T priority patent/ATE391788T1/de
Priority to PT07013576T priority patent/PT1857555E/pt
Priority to AT07013576T priority patent/ATE419364T1/de
Priority to CA2541240A priority patent/CA2541240C/en
Priority to DK04802618T priority patent/DK1670919T3/da
Priority to CA2776997A priority patent/CA2776997C/en
Publication of DE10346487A1 publication Critical patent/DE10346487A1/de
Priority to CY20081100675T priority patent/CY1108161T1/el
Priority to JP2011005485A priority patent/JP5291129B2/ja
Priority to US13/037,411 priority patent/US8247544B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels gegen chronische Entzündungserkrankungen. DOLLAR A Dabei werden Krankheits-, Zelltyp-, Gewebe- und/oder stadienspezifische Proteine und Nukleinsäuren hinsichtlich ihres geänderten Expressionsmusters identifiziert und die entsprechenden Nukleinsäuren als mögliche Angriffsziele für DNAzyme oder siRNA analysiert. Es folgt ein Design von aktiven spezifischen DNAzymen und siRNA, die an die Zielsequenz binden und diese spalten, so dass ein Arzneimittel gegen chronische Entzündungserkrankungen und Autoimmunerkrankungen zur Verfügung steht.
DE10346487A 2003-10-02 2003-10-02 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels Withdrawn DE10346487A1 (de)

Priority Applications (25)

Application Number Priority Date Filing Date Title
DE10346487A DE10346487A1 (de) 2003-10-02 2003-10-02 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
DE502004006791T DE502004006791D1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
JP2006529624A JP5013870B2 (ja) 2003-10-02 2004-10-01 細胞および／または組織および／または疾患フェーズ特異的な薬剤の製造方法
SI200430734T SI1670919T1 (sl) 2003-10-02 2004-10-01 Metoda za pripravo celic in/ali tkiva in/ali bolezni specifiäśno zdravilo
PCT/DE2004/002197 WO2005033314A2 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
KR1020067008072A KR101121818B1 (ko) 2003-10-02 2004-10-01 세포 및/또는 조직 및/또는 질환 단계 특이적 의약품의제조 방법
EP04802618A EP1670919B1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
DE502004008802T DE502004008802D1 (de) 2003-10-02 2004-10-01 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
US10/574,560 US8119789B2 (en) 2003-10-02 2004-10-01 Method for the production of a cell and/or tissue and/or disease phase specific medicament
PL04802618T PL1670919T3 (pl) 2003-10-02 2004-10-01 Sposób wytwarzania leku działającego swoiście na komórki i/lub tkanki i/lub wybrane fazy choroby
ES07013576T ES2320706T3 (es) 2003-10-02 2004-10-01 Procedimiento para la produccion de un medicamento especifico para celulas y/o tejidos y/o fases de enfermedad.
PL07013576T PL1857555T3 (pl) 2003-10-02 2004-10-01 Sposób wytwarzania leku specyficznego dla komórki i/lub tkanki i/lub fazy choroby
EP07013576A EP1857555B1 (de) 2003-10-02 2004-10-01 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
ES04802618T ES2304633T3 (es) 2003-10-02 2004-10-01 Procedimiento para la preparacion de un farmaco especifico para celulas y/o tejidos y/o fases de enfermedad.
DK07013576T DK1857555T3 (da) 2003-10-02 2004-10-01 Fremgangsmåde til fremstilling af et celle- og/eller vævs- og/eller sygdomsfase-specifikt lægemiddel
PT04802618T PT1670919E (pt) 2003-10-02 2004-10-01 Processo para a preparação de um medicamento específico para as células e/ou tecidos e/ou fases de doenças
AT04802618T ATE391788T1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
PT07013576T PT1857555E (pt) 2003-10-02 2004-10-01 Processo para a produção de um medicamento específico de células e/ou de tecidos e/ou de estádios patológicos
AT07013576T ATE419364T1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels
CA2541240A CA2541240C (en) 2003-10-02 2004-10-01 Method for the production of a cell and/or tissue and/or disease phase specific medicament
DK04802618T DK1670919T3 (da) 2003-10-02 2004-10-01 Fremgangsmåde til fremstilling af et cellespecifikt og/eller vævsspecifikt og/eller sygdomsfasespecifikt lægemiddel
CA2776997A CA2776997C (en) 2003-10-02 2004-10-01 Method for the production of a cell and/or tissue and/or disease phase specific medicament
CY20081100675T CY1108161T1 (el) 2003-10-02 2008-06-27 Μεθοδος για την παραγωγη φαρμακευτικου μεσου με κυτταρικη ειδικοτητα και/ή ιστικη ειδικοτητα και/ή ειδικοτητα φασης νοσου
JP2011005485A JP5291129B2 (ja) 2003-10-02 2011-01-14 細胞および／または組織および／または疾患フェーズ特異的な薬剤の製造方法
US13/037,411 US8247544B2 (en) 2003-10-02 2011-03-01 Method for producing a cell and/or tissue and/or disease phase specific medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10346487A DE10346487A1 (de) 2003-10-02 2003-10-02 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels

Publications (1)

Publication Number Publication Date
DE10346487A1 true DE10346487A1 (de) 2005-05-12

Family

ID=34399325

Family Applications (3)

Application Number Title Priority Date Filing Date
DE10346487A Withdrawn DE10346487A1 (de) 2003-10-02 2003-10-02 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
DE502004008802T Active DE502004008802D1 (de) 2003-10-02 2004-10-01 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
DE502004006791T Active DE502004006791D1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE502004008802T Active DE502004008802D1 (de) 2003-10-02 2004-10-01 Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
DE502004006791T Active DE502004006791D1 (de) 2003-10-02 2004-10-01 Verfahren zur herstellung eines zell- und/oder gewebe- und/oder krankheitsphasen-spezifischen arzneimittels

Country Status (14)

Country Link
US (2) US8119789B2 (de)
EP (2) EP1857555B1 (de)
JP (2) JP5013870B2 (de)
KR (1) KR101121818B1 (de)
AT (2) ATE419364T1 (de)
CA (2) CA2541240C (de)
CY (1) CY1108161T1 (de)
DE (3) DE10346487A1 (de)
DK (2) DK1670919T3 (de)
ES (2) ES2320706T3 (de)
PL (2) PL1857555T3 (de)
PT (2) PT1670919E (de)
SI (1) SI1670919T1 (de)
WO (1) WO2005033314A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
EP3501607A1 (de) 2017-12-22 2019-06-26 Sterna Biologicals GmbH & Co. KG Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI322690B (en) 2006-05-11 2010-04-01 Flysun Dev Co Ltd Short interference ribonucleic acids for treating allergic dieases
WO2010107957A2 (en) * 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JPWO2010110314A1 (ja) * 2009-03-27 2012-10-04 協和発酵キリン株式会社 核酸を含有する肺高血圧症治療剤
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
DE102011109868A1 (de) * 2011-08-10 2013-02-14 STERNA BIOLOGICALS GmbH & Co. KG. Multiple Emulsion
EP2708898A1 (de) * 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten
PL3093022T3 (pl) 2015-05-15 2020-02-28 Sterna Biologicals Gmbh & Co. Kg Inhibitory gata-3 do zastosowania do leczenia astmy powodowanej przez th2
EP3211081A1 (de) 2016-02-26 2017-08-30 Secarna Pharmaceuticals GmbH & Co. KG Neuartiger ansatz zur behandlung von entzündlichen erkrankungen
JP7065778B2 (ja) 2016-02-26 2022-05-12 セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー 炎症性障害を処置するための新規なアプローチ
US10905710B2 (en) 2016-05-24 2021-02-02 Emory University Particles with RNA cleaving nucleobase polymers and uses for managing inflammatory disorders
EP3514235B8 (de) * 2018-01-18 2024-02-14 Sterna Biologicals GmbH Zusammensetzung zur behandlung eines an colitis ulcerosa leidenden patienten sowie verwendung der zusammensetzung als arzneimittel
US20210022324A1 (en) * 2018-03-05 2021-01-28 Dr. Reddy's Institute Of Life Sciences Embryonic zebrafish models using dnazyme mediated knockdown
EP3603617A1 (de) 2018-07-30 2020-02-05 Sterna Biologicals GmbH & Co. KG Aerosolerzeugungseinrichtung zur inhalativen verabreichung einer antisense-molekül-haltigen zusammensetzung
EP3805242A1 (de) * 2019-10-07 2021-04-14 Sterna Biologicals GmbH & Co. KG Verfahren zur herstellung eines katalytisch aktiven dna-moleküls mit verbesserter aktivität und dessen verwendung in einem verfahren zur behandlung von asthma
IL304047A (en) * 2020-12-28 2023-08-01 1E Therapeutics Ltd Silencing target sites in the p21 mRNA sequence
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
WO2023052422A1 (en) 2021-09-30 2023-04-06 Sterna Biologicals Gmbh Dnazyme hydrogel formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050452A1 (en) * 1998-03-27 1999-10-07 Johnson & Johnson Research Pty. Limited Catalytic nucleic acid-based diagnostic methods
WO2001011023A1 (en) * 1999-08-04 2001-02-15 Johnson & Johnson Research Pty Ltd Treatment of inflammatory or malignant disease using dnazymes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010072475A (ko) * 1998-08-13 2001-07-31 추후제출 재발협착증을 치료하기 위한 ｄｎａ자임 및 치료 방법
AUPP810399A0 (en) * 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
WO2000051621A1 (en) 1999-03-05 2000-09-08 Epigenesis Pharmaceuticals, Inc. Method for validating/invalidating target(s) and pathways
WO2002068637A2 (en) * 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20030148971A1 (en) * 2002-02-04 2003-08-07 Handel Malcolm Lovell Treatment of inflammatory and malignant diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050452A1 (en) * 1998-03-27 1999-10-07 Johnson & Johnson Research Pty. Limited Catalytic nucleic acid-based diagnostic methods
WO2001011023A1 (en) * 1999-08-04 2001-02-15 Johnson & Johnson Research Pty Ltd Treatment of inflammatory or malignant disease using dnazymes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FINOTTO,Susetta, et.al.: Treatment of Allergic Airway Inflammation and Hyperresponsiveness by Antisense-induced Local Blockade of GATA-3 Expression. In: J. Exp. Med., Vol.193 (11), S.1247-1260 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
WO2011098285A2 (de) 2010-02-10 2011-08-18 Sterna Biologicals Gmbh & Co. Kg Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
EP2533763A2 (de) * 2010-02-10 2012-12-19 Sterna Biologicals GmbH & Co. Kg Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
US9249413B2 (en) 2010-02-10 2016-02-02 Sterna Biologicals Gmbh & Co. Kg Dermatological, pharmaceutical composition suitable for oligonucleotides
US9404110B2 (en) 2010-02-10 2016-08-02 Sterna Biologicals Gmbh & Co. Kg Dermatological, pharmaceutical composition suitable for oligonucleotides
EP2533763B1 (de) * 2010-02-10 2023-07-12 Sterna Biologicals GmbH Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
EP3501607A1 (de) 2017-12-22 2019-06-26 Sterna Biologicals GmbH & Co. KG Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung
WO2019122267A1 (de) 2017-12-22 2019-06-27 Sterna Biologicals Gmbh & Co. Kg Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung
CN111683718A (zh) * 2017-12-22 2020-09-18 燕鸥生物制剂有限两合公司 用于治疗患有慢性炎症引发的呼吸道疾病的患者的组合物以及该组合物的制备方法和用途

Also Published As

Publication number Publication date
DE502004006791D1 (de) 2008-05-21
CA2776997C (en) 2015-05-19
EP1670919A2 (de) 2006-06-21
WO2005033314A2 (de) 2005-04-14
DK1857555T3 (da) 2009-05-04
DK1670919T3 (da) 2008-07-14
WO2005033314A3 (de) 2005-09-01
US20100249216A1 (en) 2010-09-30
CY1108161T1 (el) 2014-02-12
EP1857555B1 (de) 2008-12-31
JP5291129B2 (ja) 2013-09-18
DE502004008802D1 (de) 2009-02-12
ATE419364T1 (de) 2009-01-15
US8247544B2 (en) 2012-08-21
US8119789B2 (en) 2012-02-21
PT1857555E (pt) 2009-04-07
JP2007507438A (ja) 2007-03-29
CA2541240C (en) 2014-06-03
ATE391788T1 (de) 2008-04-15
KR101121818B1 (ko) 2012-06-12
PT1670919E (pt) 2008-07-17
ES2320706T3 (es) 2009-05-27
CA2776997A1 (en) 2005-04-14
KR20060120048A (ko) 2006-11-24
SI1670919T1 (sl) 2008-08-31
JP2011074089A (ja) 2011-04-14
EP1670919B1 (de) 2008-04-09
PL1670919T3 (pl) 2008-10-31
PL1857555T3 (pl) 2009-06-30
JP5013870B2 (ja) 2012-08-29
ES2304633T3 (es) 2008-10-16
EP1857555A1 (de) 2007-11-21
US20110190377A1 (en) 2011-08-04
CA2541240A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
CY1108161T1 (el) Μεθοδος για την παραγωγη φαρμακευτικου μεσου με κυτταρικη ειδικοτητα και/ή ιστικη ειδικοτητα και/ή ειδικοτητα φασης νοσου
US20200202981A1 (en) Methods for designing guide sequences for guided nucleases
Fang et al. MicroRNAs regulate bone development and regeneration
Shah et al. Nanotechnology-based approaches for guiding neural regeneration
Lister et al. Turning over DNA methylation in the mind
Luo et al. LncRNAs: architectural scaffolds or more potential roles in phase separation
Stimpfel et al. New challenge: mitochondrial epigenetics?
Beemelmanns et al. Synthesis of the rosette-inducing factor RIF-1 and analogs
Sada et al. Near-IR laser-triggered target cell collection using a carbon nanotube-based cell-cultured substrate
Bernhardt et al. An improved method to isolate primary human osteocytes from bone
Zhou et al. Targeting RNA-splicing for SMA treatment
Bobkova et al. Neuroregeneration: regulation in neurodegenerative diseases and aging
Kim et al. Raman spectroscopy-based 3D analysis of odontogenic differentiation of human dental pulp stem cell spheroids
Zhu et al. Epigenetic regulation of organ regeneration in zebrafish
Seo et al. Effect of botulinum toxin injection and extracorporeal shock wave therapy on nerve regeneration in rats with experimentally induced sciatic nerve injury
Bennett et al. Expression patterns of DNA methylation and demethylation genes during plant development and in response to phytohormones
Kour et al. Interplay between circular RNA, microRNA, and human diseases
Tan et al. Non-coding RNAs in the regulation of hippocampal neurogenesis and potential treatment targets for related disorders
Pérez-Luz et al. Altered secretome and ROS production in olfactory mucosa stem cells derived from Friedreich’s Ataxia patients
Broccoli Reprogramming of somatic cells: iPS and iN cells
CN108148836A (zh) 一种肝再生相关长链非编码rna及其抑制剂和应用
Qiao et al. miR-328a-3p modulates the proliferative and migratory abilities of Schwann cells in peripheral nerves
Valetdinova et al. Model systems of motor neuron diseases as a platform for studying pathogenic mechanisms and searching for therapeutic agents
WO2015002892A1 (en) Methods of treating diseases by modulating mitochondrial dna deletions
Mathis et al. Light-Controlled Cell–Cell Assembly Using Photocaged Oligonucleotides

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8127 New person/name/address of the applicant

Owner name: PHILIPPS-UNIVERSITAET MARBURG, 35037 MARBURG, DE

8141 Disposal/no request for examination